Works by Dumez, H.

Results: 14

Corrigendum to "Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis".

Published in:

Sarcoma, 2021, p. 1, doi. 10.1155/2021/4653987

By:

Schöffski, P.;
Timmermans, I.;
Hompes, D.;
Stas, M.;
Boecxstaens, Veerle;
Sinnaeve, F.;
De Leyn, P.;
Coosemans, W.;
Van Raemdonck, D.;
Hauben, E.;
Sciot, R.;
Clement, P.;
Bechter, O.;
Beuselinck, B.;
Woei-A-Jin, F. J. S. H.;
Dumez, H.;
Nafteux, P.;
Wessels, T.

Publication type:

Article

Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis.

Published in:

Sarcoma, 2020, p. 1, doi. 10.1155/2020/1385978

By:

Schöffski, P.;
Timmermans, I.;
Hompes, D.;
Stas, M.;
Sinnaeve, F.;
De Leyn, P.;
Coosemans, W.;
Van Raemdonck, D.;
Hauben, E.;
Sciot, R.;
Clement, P.;
Bechter, O.;
Beuselinck, B.;
Woei-A-Jin, F. J. S. H.;
Dumez, H.;
Nafteux, P.;
Wessels, T.

Publication type:

Article

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Published in:

2006

By:

Huygh G;
Clement PMJ;
Dumez H;
Schöffski P;
Wildiers H;
Selleslach J;
Jimeno JM;
De Wever I;
Sciot R;
Duck L;
Van Oosterom AT

Publication type:

Journal Article

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients.

Published in:

Sarcoma, 2006, v. 2006, p. 1, doi. 10.1155/SRCM/2006/56282

By:

Huygh, G.;
Clement, Paul M. J.;
Dumez, H.;
Schöffski, P.;
Wildiers, H.;
Selleslach, J.;
Jimeno, J. M.;
DeWever, I.;
Sciot, R.;
Duck, L.;
Van Oosterom, A. T.

Publication type:

Article

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Published in:

British Journal of Cancer, 2012, v. 107, n. 10, p. 1665, doi. 10.1038/bjc.2012.385

By:

Beuselinck, B;
Wolter, P;
Karadimou, A;
Elaidi, R;
Dumez, H;
Rogiers, A;
Van Cann, T;
Willems, L;
Body, J-J;
Berkers, J;
Van Poppel, H;
Lerut, E;
Debruyne, P;
Paridaens, R;
Schöffski, P

Publication type:

Article

Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Published in:

2018

By:

van Cann, T.;
Loyson, T.;
Verbiest, A.;
Clement, P. M.;
Bechter, O.;
Willems, L.;
Spriet, I.;
Coropciuc, R.;
Politis, C.;
Vandeweyer, R. O.;
Schoenaers, J.;
Debruyne, P. R.;
Dumez, H.;
Berteloot, P.;
Neven, P.;
Nackaerts, K.;
Woei-A-Jin, F. J. S. H.;
Punie, K.;
Wildiers, H.;
Beuselinck, B.

Publication type:

journal article

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Published in:

2008

By:

Wolter, P.;
Stefan, C.;
Decallonne, B.;
Dumez, H.;
Bex, M.;
Carmeliet, P.;
Schöffski, P.;
Schöffski, P

Publication type:

journal article

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.

Published in:

British Journal of Cancer, 2004, v. 90, n. 12, p. 2261, doi. 10.1038/sj.bjc.6601811

By:

Wachters, Fm;
Groen, Hjm;
Maring, Jg;
Gietema, Jg;
Porro, M;
Dumez, H;
Vries, Ege De;
Oosterom, AT Van

Publication type:

Article

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.

Published in:

British Journal of Cancer, 2000, v. 83, n. 5, p. 594, doi. 10.1054/bjoc.2000.1305

By:

Paridaens, R;
Uges, D R A;
Barbet, N;
Choi, L;
Seeghers, M;
Graaf, W T A van der;
Groen, H J M;
Dumez, H;
Buuren, I Van;
Muskiet, F;
Capdeville, R;
Oosterom, A T van;
Vries, E G E de

Publication type:

Article

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.

Published in:

2011

By:

Schöffski P;
Dumez H;
Ruijter R;
Miguel-Lillo B;
Soto-Matos A;
Alfaro V;
Giaccone G

Publication type:

Journal Article

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 6, p. 1397, doi. 10.1007/s00280-011-1612-1

By:

Schöffski, P.;
Dumez, H.;
Ruijter, R.;
Miguel-Lillo, B.;
Soto-Matos, A.;
Alfaro, V.;
Giaccone, G.

Publication type:

Article

Quantitation of suspensions (MESED). Application of MESED-gC/MS in the quantitation of ifosfamide mustard in erythrocytes, plasma, and plasma water.

Published in:

Journal of Separation Science, 2001, v. 24, n. 2, p. 123, doi. 10.1002/1615-9314(20010201)24:2<123::AID-JSSC123>3.0.CO;2-8

By:

Dumez, H.;
Guetens, G.;
De Boeck, G.;
Highley, M.;
Tjaden, U. R.;
Maes, R.;
Hanauske, A.;
Van Oosterom, A. T.;
de Bruijn, E. A.

Publication type:

Article

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 734, doi. 10.1007/s10637-012-9880-0

By:

Awada, A.;
Dumez, H.;
Hendlisz, A.;
Wolter, P.;
Besse-Hammer, T.;
Uttenreuther-Fischer, M.;
Stopfer, P.;
Fleischer, F.;
Piccart, M.;
Schöffski, P.

Publication type:

Article

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies.

Published in:

2002

By:

van Kesteren, CH;
Mathôt, R. A. A;
Raymond, E;
Armand, J. P;
Dittrich, CH;
Dumez, H;
Roché, H;
Droz, J. P;
Punt, C;
Ravic, M;
Wanders, J;
Beijnen, J. H;
Fumoleau, P;
Schellens, J. H. M

Publication type:

Abstract